Aspire Biopharma Holdings, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $6,202 | — | — | — | — |
| Cost of revenue | $6,318 | — | — | — | — |
| Gross profit | -$116 | — | — | — | — |
| Research and development | $923,914 | $144,356 | — | — | — |
| Operating expenses | $19.4M | $1.2M | $1.3M | $976,345 | $25,475 |
| Operating income | -$19.4M | -$1.2M | — | — | — |
| Interest expense | $8.5M | $97,988 | — | — | — |
| Pretax income | -$24.5M | -$1.3M | — | — | — |
| Income tax expense | — | $1,013 | — | — | — |
| Net income | -$24.5M | -$1.3M | $4.5M | $3.3M | -$25,475 |
| Balance Sheet | |||||
| Current assets | $1.3M | $147,989 | $81,223 | $1.1M | $293,221 |
| Total assets | $1.3M | $147,989 | $20.0M | $300.2M | $293,221 |
| Current liabilities | $7.6M | $1.7M | $403,328 | $303,323 | $293,696 |
| Total liabilities | $7.7M | $1.7M | $403,328 | $11.1M | $293,696 |
| Stockholders' equity | -$6.4M | -$1.5M | -$487,861 | -$9.9M | -$475 |
| Cash Flow Statement | |||||
| Cash from operations | -$4.9M | -$265,186 | -$653,107 | -$1.4M | -$238,596 |
| Stock-based compensation | $14.1M | $0 | — | — | — |
| Share repurchases | — | $13.8M | $284.9M | — | — |
Shares outstanding 1.3M · Free float 98.5%
Annual filing data through FY ended December 31, 2025; float as of July 16, 2026.